Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 oral CF101 dose-finding study in moderate-to-severe dry eye disease
2010-024254-11Phase 3Completed
- Sponsor
- Can-Fite BioPharma Ltd.
- Start
- Feb 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of piclidenoson in dry eye syndrome (DED) (3 arms), sponsored by Can-Fite BioPharma Ltd. Primary endpoint: Complete clearing of corneal staining at Week 24. Started Feb 2011; status: completed.
02
Drugs
piclidenoson
03
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on 2010-024254-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024254-11.